AKYA - Akoya Biosciences, Inc. Stock Price, Fair Value and News

2.86USD-0.04 (-1.38%)Market Closed

Market Summary

USD2.86-0.04

Market Closed

-1.38%

AKYA Stock Price

View Fullscreen

AKYA RSI Chart

AKYA Valuation

Market Cap

141.2M

Price/Earnings (Trailing)

-2.08

Price/Sales (Trailing)

1.51

EV/EBITDA

-3.92

Price/Free Cashflow

-2.54

AKYA Price/Sales (Trailing)

AKYA Profitability

Operating Margin

55.99%

EBT Margin

-72.60%

Return on Equity

-207.82%

Return on Assets

-43.95%

Free Cashflow Yield

-39.38%

AKYA Fundamentals

AKYA Revenue

Revenue (TTM)

93.6M

Rev. Growth (Yr)

-14.29%

Rev. Growth (Qtr)

-30.72%

AKYA Earnings

Earnings (TTM)

-68.0M

Earnings Growth (Yr)

-24.9%

Earnings Growth (Qtr)

-117.4%

Breaking Down AKYA Revenue

Last 7 days

-32.9%

Last 30 days

-26.8%

Last 90 days

-52.0%

Trailing 12 Months

-52.0%

How does AKYA drawdown profile look like?

AKYA Financial Health

Current Ratio

3.07

Debt/Equity

2.31

Debt/Cashflow

-0.69

AKYA Investor Care

Shares Dilution (1Y)

28.59%

Diluted EPS (TTM)

-1.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	93.6M	0	0	0
2023	79.4M	85.0M	91.4M	96.6M
2022	59.6M	64.4M	69.8M	74.9M
2021	43.6M	48.1M	51.7M	54.9M
2020	0	0	0	42.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Akoya Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	ek john frederick	sold (taxes)	-65,080	4.56	-14,272	cfo
Mar 23, 2024	ramachandran niro ph.d	sold (taxes)	-9,608	4.79	-2,006	chief business officer
Mar 23, 2024	mckelligon brian	sold (taxes)	-34,176	4.79	-7,135	president and ceo
Mar 23, 2024	pla frederic	sold (taxes)	-9,608	4.79	-2,006	chief operating officer
Mar 20, 2024	mckelligon brian	acquired	2,272	0.303	7,500	president and ceo
Mar 20, 2024	mckelligon brian	sold	-37,242	4.9657	-7,500	president and ceo
Mar 13, 2024	mckelligon brian	acquired	2,272	0.303	7,500	president and ceo
Mar 13, 2024	mckelligon brian	sold	-37,042	4.939	-7,500	president and ceo
Mar 13, 2024	mckelligon brian	sold	-37,035	4.938	-7,500	president and ceo
Mar 13, 2024	shepler robert g	gifted	-	-	369,592	-

Which funds bought or sold AKYA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-39.07	-44,636	63,066	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-7,690	10,932	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-76.00	1,876	-%
May 15, 2024	Parkman Healthcare Partners LLC	added	35.96	1,009,840	4,302,800	0.53%
May 15, 2024	Kent Lake Capital LLC	sold off	-100	-570,155	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-55.8	-61,590	45,483	-%
May 15, 2024	Blue Water Life Science Advisors, LP	unchanged	-	-892,579	22,032,600	20.72%
May 15, 2024	STEPHENS INC /AR/	reduced	-28.26	-26,340	58,489	-%
May 15, 2024	Polar Capital Holdings Plc	unchanged	-	-300,153	7,409,060	0.04%
May 15, 2024	AMERIPRISE FINANCIAL INC	reduced	-12.93	-31,876	163,446	-%

Are Funds Buying or Selling AKYA?

Are funds buying AKYA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AKYA

No. of Funds

Unveiling Akoya Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	telegraph hill partners iii, l.p.	36.0%	17,675,247	SC 13G/A
Feb 12, 2024	psc capital partners llc	7.2%	3,517,360	SC 13G/A
Jan 03, 2024	schindel yair chaim	5.85%	2,871,406	SC 13G/A
Jun 13, 2023	schindel yair chaim	5.16%	2,500,000	SC 13G
Feb 15, 2023	psc capital partners llc	7.2%	2,717,360	SC 13G/A
Feb 14, 2023	psc capital partners llc	7.2%	2,717,360	SC 13G/A
Feb 07, 2023	hudson executive capital lp	4.99%	1,892,204	SC 13D/A
Dec 02, 2022	hudson executive capital lp	6.4%	2,447,558	SC 13D/A
Sep 13, 2022	hudson executive capital lp	9.8%	3,697,558	SC 13D/A
Feb 25, 2022	psc capital partners llc	7.6%	2,813,771	SC 13G

Recent SEC filings of Akoya Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading

Peers (Alternatives to Akoya Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Akoya Biosciences, Inc. News

Latest updates

Akoya Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-30.7%	18,350,000	26,487,000	25,215,000	23,521,000	21,410,000	21,219,000	18,852,000	17,894,000	16,894,000	16,158,000	13,476,000	13,071,000	12,212,000	12,908,000	9,954,000	8,560,000	11,021,000
Cost Of Revenue	1.1%	9,971,000	9,867,000	9,939,000	11,405,000	9,117,000	9,173,000	7,945,000	7,553,000	6,798,000	5,932,000	5,023,000	4,937,000	4,807,000	5,000,000	3,920,000	3,290,000	4,325,000
Gross Profit	-49.6%	8,379,000	16,620,000	15,276,000	12,116,000	12,293,000	12,046,000	10,907,000	10,341,000	10,096,000	10,226,000	8,453,000	8,134,000	7,405,000	7,908,000	6,034,000	5,270,000	6,696,000
Operating Expenses	15.0%	29,964,000	26,059,000	26,827,000	31,358,000	29,729,000	29,637,000	27,560,000	26,649,000	25,650,000	27,006,000	19,192,000	14,512,000	12,806,000	11,057,000	9,701,000	9,102,000	8,059,000
S&GA Expenses	5.1%	19,863,000	18,898,000	19,017,000	22,708,000	21,758,000	20,948,000	19,922,000	20,590,000	18,193,000	19,046,000	13,725,000	10,066,000	8,179,000	6,816,000	5,712,000	5,105,000	6,349,000
R&D Expenses	18.9%	5,554,000	4,670,000	5,173,000	6,273,000	5,773,000	6,433,000	5,466,000	5,598,000	5,714,000	5,563,000	3,999,000	2,947,000	3,192,000	2,532,000	2,279,000	2,420,000	2,372,000
EBITDA Margin	-12.4%	-0.55	-0.49	-0.62	-0.74	-0.77	-0.81	-0.86	-0.85	-0.73	-0.65	-0.46	-0.35	-	-	-	-	-
Interest Expenses	13.7%	2,243,000	1,972,000	1,973,000	1,912,000	1,793,000	1,288,000	899,000	652,000	638,000	726,000	652,000	652,000	638,000	871,000	464,000	454,000	457,000
Income Taxes	386.4%	63,000	-22,000	15,000	18,000	29,000	-26,000	21,000	106,000	22,000	-117,000	-11,000	-6,000	-6,000	-26,000	-9,000	39,000	38,000
Earnings Before Taxes	-116.4%	-23,421,000	-10,824,000	-12,901,000	-20,785,000	-18,773,000	-18,901,000	-17,851,000	-17,389,000	-16,377,000	-17,790,000	-11,628,000	-5,569,000	-8,088,000	-5,720,000	-4,293,000	-4,546,000	-2,105,000
EBT Margin	-10.9%	-0.73	-0.65	-0.78	-0.90	-0.92	-0.94	-0.99	-0.98	-0.86	-0.78	-0.60	-0.49	-	-	-	-	-
Net Income	-117.4%	-23,484,000	-10,802,000	-12,916,000	-20,803,000	-18,802,000	-18,875,000	-17,872,000	-17,495,000	-16,399,000	-17,673,000	-11,617,000	-5,563,000	-8,082,000	-5,694,000	-4,284,000	-4,585,000	-2,143,000
Net Income Margin	-10.9%	-0.73	-0.66	-0.78	-0.90	-0.92	-0.94	-0.99	-0.98	-0.86	-0.78	-0.60	-0.49	-	-	-	-	-
Free Cashflow	-250.2%	-21,634,000	-6,178,000	-14,585,000	-13,227,000	-20,562,000	-10,876,000	-15,960,000	-14,950,000	-19,070,000	-7,219,000	-15,270,000	-13,362,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-14.2%	155	180	177	189	154	176	176	184	187	191	195	206	74.00	78.00
Current Assets	-16.4%	102	122	117	126	92.00	112	112	120	126	141	146	157	24.00	29.00
Cash Equivalents	-83.5%	14.00	83.00	79.00	93.00	60.00	74.00	52.00	47.00	94.00	113	120	136	12.00	18.00
Inventory	28.6%	23.00	18.00	19.00	16.00	15.00	14.00	13.00	13.00	11.00	9.00	6.00	7.00	5.00	4.00
Net PPE	-16.5%	9.00	11.00	11.00	11.00	10.00	10.00	10.00	9.00	8.00	7.00	6.00	6.00	6.00	6.00
Goodwill	0%	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00	18.00
Liabilities	-3.6%	122	127	115	117	112	117	101	93.00	81.00	70.00	58.00	59.00	64.00	60.00
Current Liabilities	-6.1%	33.00	35.00	36.00	37.00	33.00	37.00	32.00	34.00	32.00	28.00	17.00	18.00	21.00	17.00
Long Term Debt	0.3%	75.00	75.00	64.00	64.00	63.00	63.00	53.00	43.00	33.00	32.00	32.00	32.00	33.00	33.00
LT Debt, Non Current	-100.0%	-	75.00	64.00	64.00	63.00	63.00	53.00	43.00	33.00	32.00	32.00	32.00	33.00	33.00
Shareholder's Equity	-39.1%	33.00	54.00	62.00	72.00	42.00	59.00	75.00	91.00	107	121	137	148	-	-
Retained Earnings	-10.2%	-253	-230	-219	-206	-185	-166	-147	-130	-112	-96.11	-78.43	-66.82	-61.25	-52.28
Additional Paid-In Capital	0.9%	286	284	281	278	228	225	223	221	219	217	216	215	-	-
Shares Outstanding	0.5%	49.00	49.00	49.00	49.00	38.00	38.00	38.00	38.00	37.00	37.00	23.00	16.00	-	-
Float	-	-	-	-	186	-	-	-	222	-	-	-	320	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-272.9%	-20,824	-5,584	-13,753	-11,804	-19,758	-10,007	-12,171	-13,386	-17,932	-5,854	-13,395	-12,415	-4,404	-2,147	-1,740	-1,999	-957
Share Based Compensation	0.1%	2,566	2,564	2,878	2,620	2,375	2,120	2,044	1,721	1,545	1,411	1,158	1,216	254	54.00	60.00	51.00	312
Cashflow From Investing	-8118.4%	-48,817	-594	-832	-1,423	6,196	22,131	7,266	-42,338	-1,138	-1,365	-1,875	-947	-907	9,653	-902	-588	-1,435
Cashflow From Financing	-104.0%	-444	11,077	-141	46,327	-419	10,270	9,860	8,667	-71.00	149	-44.00	136,934	-4.00	5,687	40.00	2,419	-2,660

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AKYA Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 18,350	$ 21,410
Cost of goods sold	9,971	9,117
Gross profit	8,379	12,293
Operating expenses:
Selling, general and administrative	19,863	23,124
Research and development	5,554	6,378
Change in fair value of contingent consideration	179	227
Impairment	2,971	0
Restructuring	1,397
Total operating expenses	29,964	29,729
Loss from operations	(21,585)	(17,436)
Other income (expense):
Interest expense	(2,612)	(2,054)
Interest income	937	765
Other expense, net	(161)	(48)
Loss before provision for income taxes	(23,421)	(18,773)
Provision for income taxes	(63)	(29)
Net loss	$ (23,484)	$ (18,802)
Net loss per share attributable to common stockholders, basic	$ (0.48)	$ (0.49)
Net loss per share attributable to common stockholders, diluted	$ (0.48)	$ (0.49)
Weighted-average shares outstanding, basic	49,188,170	38,326,024
Weighted-average shares outstanding, diluted	49,188,170	38,326,024
Product
Revenue	$ 12,140	$ 15,524
Cost of goods sold	6,723	5,751
Service and other
Revenue	6,210	5,886
Cost of goods sold	$ 3,248	$ 3,366

AKYA Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 13,039	$ 83,125
Marketable securities	48,536
Accounts receivable, net	13,473	16,994
Inventories, net	22,988	17,877
Prepaid expenses and other current assets	3,793	3,794
Total current assets	101,829	121,790
Property and equipment, net	8,964	10,729
Restricted cash	700	699
Demo inventory, net	726	893
Intangible assets, net	16,699	17,412
Goodwill	18,262	18,262
Operating lease right of use assets, net	5,568	8,365
Financing lease right of use assets, net	1,348	1,562
Other assets	654	657
Total assets	154,750	180,369
Current liabilities
Accounts payable	10,747	11,776
Accrued expenses and other current liabilities	12,462	13,433
Current portion of operating lease liabilities	2,654	2,681
Current portion of financing lease liabilities	718	767
Deferred revenue	6,612	6,688
Total current liabilities	33,193	35,345
Deferred revenue, net of current portion	2,928	3,193
Long-term debt, net of debt discount	75,469	75,254
Deferred tax liability, net	75	38
Operating lease liabilities, net of current portion	5,713	6,238
Financing lease liabilities, net of current portion	634	766
Contingent consideration liability, net of current portion	4,015	5,765
Total liabilities	122,027	126,599
Stockholders' equity:
Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common Stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 49,340,417 and 49,117,738 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	2	2
Additional paid in capital	286,292	283,839
Accumulated deficit	(253,555)	(230,071)
Accumulated other comprehensive loss	(16)
Total stockholders' equity	32,723	53,770
Total liabilities and stockholders' equity	$ 154,750	$ 180,369

About Akoya Biosciences, Inc.

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Brian McKelligon
WEBSITE	akoyabio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	369

Akoya Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Akoya Biosciences, Inc.? What does AKYA stand for in stocks?

AKYA is the stock ticker symbol of Akoya Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akoya Biosciences, Inc. (AKYA)?

As of Fri May 17 2024, market cap of Akoya Biosciences, Inc. is 141.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKYA stock?

You can check AKYA's fair value in chart for subscribers.

What is the fair value of AKYA stock?

You can check AKYA's fair value in chart for subscribers. The fair value of Akoya Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akoya Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKYA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akoya Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether AKYA is over valued or under valued. Whether Akoya Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Akoya Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKYA.

What is Akoya Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AKYA's PE ratio (Price to Earnings) is -2.08 and Price to Sales (PS) ratio is 1.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKYA PE ratio will change depending on the future growth rate expectations of investors.